

2019 Future of Neuromyelitis Optica (Devic's Syndrome) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/263AFEB01CEN.html>

Date: February 2019

Pages: 80

Price: US\$ 2,199.00 (Single User License)

ID: 263AFEB01CEN

Abstracts

The global demand for Neuromyelitis Optica (Devic's Syndrome) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Neuromyelitis Optica (Devic's Syndrome) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Neuromyelitis Optica (Devic's Syndrome) pipeline companies from advancing their products into Phase 3 or Phase 4.

Neuromyelitis Optica (Devic's Syndrome) Report Description-

The 2019 pipeline study on Neuromyelitis Optica (Devic's Syndrome) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Neuromyelitis Optica (Devic's Syndrome) pipeline compounds.

The Neuromyelitis Optica (Devic's Syndrome) pipeline guide presents information on all active drugs currently being developed for Neuromyelitis Optica (Devic's Syndrome). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-

registration phases.

Details of current status, R&D progress and latest developments for every Neuromyelitis Optica (Devic's Syndrome) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Neuromyelitis Optica (Devic's Syndrome) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Neuromyelitis Optica (Devic's Syndrome) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Neuromyelitis Optica (Devic's Syndrome) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Neuromyelitis Optica (Devic's Syndrome) pipeline report includes-

An overview of Neuromyelitis Optica (Devic's Syndrome) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Neuromyelitis Optica (Devic's Syndrome) pipeline

Company wise list of Neuromyelitis Optica (Devic's Syndrome) pipeline

Mechanism of Action wise Neuromyelitis Optica (Devic's Syndrome) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Neuromyelitis Optica (Devic's Syndrome) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Neuromyelitis Optica (Devic's Syndrome) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Neuromyelitis Optica (Devic's Syndrome) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Neuromyelitis Optica (Devic's Syndrome) Drugs under active development, H1-2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Neuromyelitis Optica (Devic's Syndrome) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Neuromyelitis Optica (Devic's Syndrome) Pipeline Candidates

4 ABIDE THERAPEUTICS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 4.1 Abide Therapeutics Inc Business Profile
- 4.2 Abide Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration

- 4.3.4 Orphan Drug/Fast Track/Special Designation
- 4.3.5 Geography
- 4.3.6 Type of Molecular Entity
- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ACER THERAPEUTICS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 5.1 Acer Therapeutics Inc Business Profile
- 5.2 Acer Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ALEXION PHARMACEUTICALS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 6.1 Alexion Pharmaceuticals Inc Business Profile
- 6.2 Alexion Pharmaceuticals Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity

- 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ANVIL BIOSCIENCES NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 7.1 Anvil Biosciences Business Profile
- 7.2 Anvil Biosciences Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 BIOGEN INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 8.1 Biogen Inc Business Profile
- 8.2 Biogen Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action

- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIONURE FARMA SL NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 9.1 Bionure Farma SL Business Profile
- 9.2 Bionure Farma SL Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CHORD THERAPEUTICS SARL NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 10.1 Chord Therapeutics Sarl Business Profile
- 10.2 Chord Therapeutics Sarl Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CHUGAI PHARMACEUTICAL CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 11.1 Chugai Pharmaceutical Co Ltd Business Profile
- 11.2 Chugai Pharmaceutical Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CLENE NANOMEDICINE INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 12.1 Clene Nanomedicine Inc Business Profile
- 12.2 Clene Nanomedicine Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 ENDECE LLC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 13.1 Endece LLC Business Profile
- 13.2 Endece LLC Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 ENHANX BIOPHARM INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 14.1 EnhanX Biopharm Inc Business Profile
- 14.2 EnhanX Biopharm Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 15.1 Fundacio Clinic per a la Recerca Biomedica Business Profile
- 15.2 Fundacio Clinic per a la Recerca Biomedica Neuromyelitis Optica (Devic's

Syndrome) Drug Details

15.3 Drug Snapshot

15.3.1 Originator

15.3.2 Collaborator/Co-Developer

15.3.3 Route of Administration

15.3.4 Orphan Drug/Fast Track/Special Designation

15.3.5 Geography

15.3.6 Type of Molecular Entity

15.3.7 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 HANALL BIOPHARMA CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

16.1 HanAll Biopharma Co Ltd Business Profile

16.2 HanAll Biopharma Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 IMSTEM BIOTECHNOLOGY INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

17.1 Imstem Biotechnology Inc Business Profile

17.2 Imstem Biotechnology Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details

17.3 Drug Snapshot

17.3.1 Originator

- 17.3.2 Collaborator/Co-Developer
- 17.3.3 Route of Administration
- 17.3.4 Orphan Drug/Fast Track/Special Designation
- 17.3.5 Geography
- 17.3.6 Type of Molecular Entity
- 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 LFB SA NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 18.1 LFB SA Business Profile
- 18.2 LFB SA Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 NIHON PHARMACEUTICALS CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 19.1 Nihon Pharmaceuticals Co Ltd Business Profile
- 19.2 Nihon Pharmaceuticals Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation

- 19.3.5 Geography
- 19.3.6 Type of Molecular Entity
- 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 ORION BIOSCIENCE INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 20.1 Orion BioScience Inc Business Profile
- 20.2 Orion BioScience Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 TOLERION INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 21.1 Tolerion Inc Business Profile
- 21.2 Tolerion Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status

- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 VICORE PHARMA AB NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 22.1 Vicore Pharma AB Business Profile
- 22.2 Vicore Pharma AB Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 VIELA BIO NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 23.1 Viela Bio Business Profile
- 23.2 Viela Bio Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details

23.7 Latest Drug Developments

24 YANTAI RONGCHANG PHARMACEUTICAL CO.,LTD. NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

24.1 Yantai Rongchang Pharmaceutical Co.,Ltd. Business Profile

24.2 Yantai Rongchang Pharmaceutical Co.,Ltd. Neuromyelitis Optica (Devic's Syndrome) Drug Details

24.3 Drug Snapshot

24.3.1 Originator

24.3.2 Collaborator/Co-Developer

24.3.3 Route of Administration

24.3.4 Orphan Drug/Fast Track/Special Designation

24.3.5 Geography

24.3.6 Type of Molecular Entity

24.3.7 Current Status

24.4 Drug Overview

24.5 Drug Mechanism of Action

24.6 Clinical/Pre-clinical Trial Details

24.7 Latest Drug Developments

25. LATEST NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) DRUG PIPELINE DEVELOPMENTS, 2019

26. APPENDIX

26.1 About Us

26.2 Sources and Methodology

26.3 Contact Information

I would like to order

Product name: 2019 Future of Neuromyelitis Optica (Devic's Syndrome) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/263AFEBBC01CEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/263AFEBBC01CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970